[1] [1] CHANG J W. Acral melanoma: a unique disease in Asia[J]. JAMA Dermatol, 2013, 149(11): 1272-1273.

[2] [2] SIEGEL R L, GIAQUINTO A N, JEMAL A. Cancer statistics, 2024[J]. CA A Cancer J Clin, 2024, 74(1): 12-49.

[3] [3] HAN B F, ZHENG R S, ZENG H M, et al. Cancer incidence and mortality in China, 2022[J]. J Natl Cancer Cent, 2024, 4(1): 47-53.

[4] [4] PEREZ M C, MESSINA J L, KARAPETYAN L, et al. Acral melanoma: clinical advances and hope for the future[J]. Clin Adv Hematol Oncol, 2023, 21(8): 400-409.

[5] [5] ZHANG Y Q, LAN S J, WU D. Advanced acral melanoma therapies: current status and future directions[J]. Curr Treat Options Oncol, 2022, 23(10): 1405-1427.

[7] [7] KONG Y, SI L, GUO J, et al. Aberrations ofKIT,BRAF,NRAS, andPDGFRAin Chinese melanoma patients and their significance: large, scale analysis of 644 patients[J]. J Clin Oncol, 2011, 29(15_suppl): 8568.

[8] [8] SI L, KONG Y, XU X W, et al. Prevalence ofBRAFV600E mutation in Chinese melanoma patients: large scale analysis ofBRAFandNRASmutations in a 432-case cohort[J]. Eur J Cancer, 2012, 48(1): 94-100.

[9] [9] OLIVIER T, PRASAD V. Neoadjuvant followed by adjuvant pembrolizumab in melanoma: time biases in the data analysis of the SWOG S1801 trial[J]. Transl Oncol, 2024, 45: 101959.

[10] [10] BLANK C U, LUCAS M W, SCOLYER R A, et al. Neoadjuvant nivolumab and ipilimumab in resectable stage Ⅲ melanoma[J]. N Engl J Med, 2024, 391(18): 1696-1708.

[11] [11] VERSLUIS J M, MENZIES A M, SIKORSKA K, et al. Survival update of neoadjuvant ipilimumab plus nivolumab in macroscopic stage Ⅲ melanoma in the OpACIN and OpACIN-neo trials[J]. Ann Oncol, 2023, 34(4): 420-430.

[12] [12] HIEKEN T J, NELSON G D, FLOTTE T J, et al. Neoadjuvant cobimetinib and atezolizumab with or without vemurafenib for high-risk operable stage Ⅲ melanoma: the phase ⅡNeoACTIVATE trial[J]. Nat Commun, 2024, 15(1): 1430.

[13] [13] LONG G V, CARLINO M S, AU-YEUNG G, et al. Neoadjuvant pembrolizumab, dabrafenib and trametinib inBRAFV600-mutant resectable melanoma: the randomized phase 2 NeoTrio trial[J]. Nat Med, 2024, 30(9): 2540-2548.

[14] [14] LONG G V, BLANK C U, AMARIA R N, et al. LBA41 Longterm survival with neoadjuvant therapy in melanoma: updated pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC)[J]. Ann Oncol, 2024, 35: S1232.

[15] [15] MAO L L, LI C L, DAI J, et al. Neoadjuvant camrelizumab plus apatinib and temozolomide for resectable stage Ⅱ/Ⅲ acral melanoma: the CAP 03-NEO trial[C]. Chicago: ASCO, 2025.

[16] [16] HANSEN I, RNGER A, NOEBEL C, et al. Prevention of amputation by neoadjuvant therapy with pembrolizumab in acrolentiginous melanoma[J]. J Eur Acad Dermatol Venereol, 2024, 38(9): e820-e822.

[17] [17] LIU J Y, WANG X, LI Z W, et al. Neoadjuvant oncolytic virus orienx010 and toripalimab in resectable acral melanoma: a phase Ⅰb trial[J]. Signal Transduct Target Ther, 2024, 9(1): 318.

[18] [18] National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: melanoma: cutaneous. Version 2. 2024[EB/OL]. [2025-07-15]. https://www.nccn.org/professionals/physician_gls/pdf/melanoma.pdf.

[19] [19] ARAK H, ERKILI S, YASLIKAYA , et al. The effectiveness of adjuvant PD-1 inhibitors in patients with surgically resected stage Ⅲ/Ⅳ acral melanoma[J]. J Immunother, 2024, 47(5): 182-189.

[23] [23] BLOEM M, VAN NOT O J, AARTS M J B, et al. Adjuvant treatment with anti-PD-1 in acral melanoma: a nationwide study[J]. Int J Cancer, 2024, 155(8): 1455-1465.

[24] [24] BLOEM M, DE MEZA M M, AARTS M J B, et al. Adjuvant BRAF/MEK versus anti-PD-1 inBRAF-mutant melanoma: propensity score-matched recurrence-free, distant metastasis-free, and overall survival analysis[J]. J Clin Oncol, 2024, 42(16_suppl): 9573.

[25] [25] BAI X, LAWLESS A R, CZAPLA J A, et al. Benefit, recurrence pattern, and toxicity to adjuvant anti-PD-1 monotherapy varies by ethnicity and melanoma subtype: an international multicenter cohort study[J]. JAAD Int, 2024, 15: 105-114.

[26] [26] HU X, XU Y, SUN Y, et al. Toripalimab (anti-PD-1) plus recombinant human endostatin as adjuvant therapy in patients with resected stage Ⅲ melanoma: interim analysis of an openlabel phase Ⅱ trial[J]. J Clin Oncol, 2024, 42(16_suppl): e21557.

[27] [27] JOHNSON D B, PENG C, ABRAMSON R G, et al. Clinical activity of ipilimumab in acral melanoma: a retrospective review[J]. Oncologist, 2015, 20(6): 648-652.

[28] [28] ZHENG Q Y, LI J R, ZHANG H L, et al. Immune checkpoint inhibitors in advanced acral melanoma: a systematic review[J]. Front Oncol, 2020, 10: 602705.

[29] [29] CUI C L, CHEN Y, LUO Z G, et al. Safety and efficacy of Pucotenlimab (HX008)-a humanized immunoglobulin G4 monoclonal antibody in patients with locally advanced or metastatic melanoma: a single-arm, multicenter, phase Ⅱ study[J]. BMC Cancer, 2023, 23(1): 121.

[30] [30] SI L, ZHANG X S, SHU Y Q, et al. Pembrolizumab in Chinese patients with advanced melanoma: 3-year follow-up of the KEYNOTE-151 study[J]. Front Immunol, 2022, 13: 882471.

[31] [31] TANG B, CHI Z, CHEN Y, et al. Safety, efficacy, and biomarker analysis of toripalimab in previously treated advanced melanoma: results of the POLARIS-01 multicenter phase Ⅱ trial[J]. Clin Cancer Res, 2020, 26(16): 4250-4259.

[32] [32] VAN BREESCHOTEN J, WOUTERS M W J M, HILARIUS D L, et al. First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy inBRAFV600-mutant advanced melanoma patients: a propensity-matched survival analysis[J]. Br J Cancer, 2021, 124(7): 1222-1230.

[33] [33] HU T, SUN W, XU Y, et al. Combination of pembrolizumab plus temozolomide therapy in unresectable and advanced melanoma: a multicenter retrospective analysis in China[J]. Ann Transl Med, 2021, 9(21): 1625.

[34] [34] LEE J, CHANG J S, ROH M R, et al. Clinical outcomes of immune checkpoint blocker therapy for malignant melanoma in Korean patients: potential clinical implications for a combination strategy involving radiotherapy[J]. Cancer Res Treat, 2020, 52(3): 730-738.

[35] [35] MAIO M, CARLINO M S, JOSHUA A M, et al. KEYNOTE-022: pembrolizumab with trametinib in patients withBRAFwildtype melanoma or advanced solid tumours irrespective ofBRAFmutation[J]. Eur J Cancer, 2022, 160: 1-11.

[36] [36] MCARTHUR G A, GUTZMER R, STROYAKOVSKIY D, et al. Overall survival (OS) with first-line atezolizumab (A) or placebo (P) in combination with vemurafenib (V) and cobimetinib (C) inBRAFV600 mutation-positive advanced melanoma: second interim OS analysis of the phase 3 IMspire150 study[J]. J Clin Oncol, 2022, 40(16_suppl): 9547.

[37] [37] ATKINS M B, LEE S J, CHMIELOWSKI B, et al. DREAMseq (doublet, randomized evaluation in advanced melanoma sequencing): a phase Ⅲ trial-ECOG-ACRIN EA6134[J]. J Clin Oncol, 2021, 39(36_suppl): 356154.

[38] [38] SI L, QI Z, DAI J, et al. A single-arm, phase Ⅱ clinical study of imatinib mesylate/toripalimab combo in patients (pts) with advanced melanoma harboringc-Kitmutation or amplification[J]. Ann Oncol, 2022, 33: S919.

[39] [39] WANG J H, JIANG H, HUANG F X, et al. Clinical features and response to systemic therapy inNRAS-mutant Chinese melanoma patients[J]. J Cancer Res Clin Oncol, 2023, 149(2): 701-708.

[40] [40] SI L, LI C L, BAI X, et al. A phase Ⅱ clinical trial of camrelizumab (CAM, an IgG4 antibody against PD-1) combined with apatinib (APA, a VEGFR-2 tyrosine kinase inhibitor) and temozolomide (TMZ) as the first-line treatment for patients (pts) with advanced acral melanoma (AM)[J]. J Clin Oncol, 2022, 40(16_suppl): 9508.

[41] [41] MAO L L, SI L, LI C L, et al. Phase Ⅱ clinical trial of camrelizumab combined with famitinib for advanced acral and mucosal melanoma[J]. J Clin Oncol, 2023, 41(16_suppl): 9550.

[42] [42] BHAVE P, AHMED T, LO S N, et al. Efficacy of anti-PD-1 and ipilimumab alone or in combination in acral melanoma[J]. J Immunother Cancer, 2022, 10(7): e004668.

[43] [43] Tawbi H A, Schadendorf D, Lipson E J, et al. Relatlimab and nivolumab versus nivolumab in untreated advanced melanoma[J]. New England Journal of Medicine, 2022, 386(1): 24-34.

[44] [44] BAI X, LI M, CHEN Y, et al. Updated safety and efficacy results from the phase Ⅰ study of either LBL-007 (an anti-LAG-3 antibody) in combination with toripalimab (an anti-PD-1 antibody) or LBL-007 in combination with toripalimab and axitinib in patients with advanced melanoma[J]. J Clin Oncol, 2023, 41(16_suppl): 9541.

[45] [45] SCHADENDORF D, TAWBI H A, LIPSON E J, et al. Efficacy and safety of first-line (1L) nivolumab plus relatlimab (NIVO+RELA) versus NIVO plus ipilimumab (NIVO+IPI) in advanced melanoma: an indirect treatment comparison (ITC) using patient-level data (PLD)[J]. J Clin Oncol, 2023, 41(16_suppl): 9552.

[46] [46] ASCIERTO P A, DUMMER R, GAUDY-MARQUESTE C, et al. Efficacy and safety of triplet nivolumab, relatlimab, and ipilimumab (NIVO+RELA+IPI) in advanced melanoma: results from RELATIVITY-048[J]. J Clin Oncol, 2024, 42(16_suppl): 9504.

[47] [47] MORI T, NAMIKAWA K, YAMAZAKI N, et al. Efficacy of salvage therapies for advanced acral melanoma after anti-PD-1 monotherapy failure: a multicenter retrospective study of 108 Japanese patients[J]. Front Med (Lausanne), 2023, 10: 1229937.

[48] [48] WANG X, XU W R, CHI Z H, et al. Chemotherapy combined with antiangiogenic drugs as salvage therapy in advanced melanoma patients progressing on PD-1 immunotherapy[J]. Transl Oncol, 2021, 14(1): 100949.

[49] [49] WEICHENTHAL M, SVANE I M, KANDOLF SEKULOVIC L, et al. EMRseq: registry-based outcome analysis on 1 000 patients withBRAFV600-mutated metastatic melanoma in Europe treated with either immune checkpoint or BRAF-/MEK inhibition[J]. J Clin Oncol, 2022, 40(16_suppl): 9540.

[50] [50] CHEN Q Q, ZHAO Y, LI P P, et al. Survival analysis of comprehensive treatment in Chinese patients with metastatic melanoma: a retrospective analysis[J]. Skin Res Technol, 2024, 30(2): e13546.

[51] [51] ZHOU L, SHAO L Z, GAO S Y, et al. Impact of response patterns for patients with advanced acral melanoma treated with anti-programmed death-1 monotherapy[J]. Br J Dermatol, 2023, 188(1): 112-121.